MX2018008978A - Receptores de antigenos quimericos que se dirigen a la variante iii del receptor de factor de crecimiento epidermico. - Google Patents

Receptores de antigenos quimericos que se dirigen a la variante iii del receptor de factor de crecimiento epidermico.

Info

Publication number
MX2018008978A
MX2018008978A MX2018008978A MX2018008978A MX2018008978A MX 2018008978 A MX2018008978 A MX 2018008978A MX 2018008978 A MX2018008978 A MX 2018008978A MX 2018008978 A MX2018008978 A MX 2018008978A MX 2018008978 A MX2018008978 A MX 2018008978A
Authority
MX
Mexico
Prior art keywords
growth factor
factor receptor
epidermal growth
chimeric antigen
antigen receptors
Prior art date
Application number
MX2018008978A
Other languages
English (en)
Spanish (es)
Inventor
Smith Julianne
Kwan Wong Oi
Ching Chou Joyce
Brunnhilde Dusseaux Mathilde
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2018008978A publication Critical patent/MX2018008978A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2018008978A 2016-01-21 2017-01-10 Receptores de antigenos quimericos que se dirigen a la variante iii del receptor de factor de crecimiento epidermico. MX2018008978A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662281533P 2016-01-21 2016-01-21
US201662431758P 2016-12-08 2016-12-08
PCT/IB2017/050108 WO2017125830A1 (en) 2016-01-21 2017-01-10 Chimeric antigen receptors targeting epidermal growth factor receptor variant iii

Publications (1)

Publication Number Publication Date
MX2018008978A true MX2018008978A (es) 2019-01-10

Family

ID=57868301

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008978A MX2018008978A (es) 2016-01-21 2017-01-10 Receptores de antigenos quimericos que se dirigen a la variante iii del receptor de factor de crecimiento epidermico.

Country Status (22)

Country Link
US (3) US10259876B2 (enExample)
EP (1) EP3405481B1 (enExample)
JP (2) JP6823659B2 (enExample)
KR (1) KR102479606B1 (enExample)
CN (1) CN108699124A (enExample)
AU (1) AU2017208834B2 (enExample)
BR (1) BR112018014585A2 (enExample)
CA (1) CA2954014A1 (enExample)
DK (1) DK3405481T5 (enExample)
EA (1) EA201891641A1 (enExample)
ES (1) ES2942362T3 (enExample)
IL (1) IL260666B2 (enExample)
MX (1) MX2018008978A (enExample)
MY (1) MY192474A (enExample)
NZ (1) NZ744821A (enExample)
PH (1) PH12018501473B1 (enExample)
RU (1) RU2751662C2 (enExample)
SA (1) SA518392058B1 (enExample)
SG (2) SG10202111458RA (enExample)
TW (2) TWI755547B (enExample)
UA (1) UA125252C2 (enExample)
WO (1) WO2017125830A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018005348A (es) 2015-10-30 2018-08-14 Aleta Biotherapeutics Inc Composiciones y metodos para transduccion de tumores.
CA3002674A1 (en) 2015-10-30 2017-05-04 Aleta Biotherapeutics Inc. Compositions and methods for treatment of cancer
US10259876B2 (en) 2016-01-21 2019-04-16 Pfizer Inc. Chimeric antigen receptors targeting epidermal growth factor receptor variant III
DK3405490T3 (da) 2016-01-21 2022-01-10 Pfizer Mono- og bispecifikke antistoffer mod epidermal vækstfaktorreceptor variant iii og cd3 og anvendelser deraf
MA46995A (fr) 2016-12-03 2019-10-09 Acerta Pharma Bv Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
KR20200054160A (ko) 2017-06-02 2020-05-19 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법
US12090170B2 (en) 2018-04-06 2024-09-17 The Regents Of The University Of California Methods of treating glioblastomas
WO2019195586A1 (en) * 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
TW202020146A (zh) * 2018-07-26 2020-06-01 大陸商南京傳奇生物科技有限公司 含nef之t細胞及其產生方法
CN109265561B (zh) * 2018-09-25 2021-05-25 山东兴瑞生物科技有限公司 抗EGFRvⅢ安全型嵌合抗原受体、其制备方法、利用其修饰的NK细胞及应用
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020106621A1 (en) * 2018-11-19 2020-05-28 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
PE20211915A1 (es) * 2018-12-01 2021-09-28 Allogene Therapeutics Inc Receptores de antigenos quimericos dirigidos al antigeno de maduracion de celulas b y sus metodos de uso
TWI881476B (zh) * 2018-12-21 2025-04-21 瑞士商赫孚孟拉羅股份公司 結合cd3之抗體
AU2020209991B2 (en) * 2019-01-17 2024-11-14 Immunocore Limited Formulations
CN111454358A (zh) * 2019-01-18 2020-07-28 四川科伦博泰生物医药股份有限公司 一种嵌合抗原受体及其应用
CN113710697A (zh) * 2019-03-15 2021-11-26 美国政府(由卫生和人类服务部的部长所代表) 嵌合衔接子和激酶信号传导蛋白及其在免疫疗法中的用途
EP3994173A1 (en) * 2019-07-02 2022-05-11 The United States of America, as represented by the Secretary, Department of Health and Human Services Monoclonal antibodies that bind egfrviii and their use
US20220288118A1 (en) * 2019-07-31 2022-09-15 Forty Seven, Inc. Depletion regimes for engineered t-cell or nk-cell therapy
EP4031583A4 (en) * 2019-09-16 2023-11-15 Fred Hutchinson Cancer Center CHIMERIC RECEPTOR PROTEINS AND THEIR USES
AU2020358898B2 (en) * 2019-10-01 2025-10-16 Epsilogen Ltd Hybrid antibody
EP4081537A1 (en) * 2019-12-23 2022-11-02 Cellectis New mesothelin specific chimeric antigen receptors (car) for solid tumors cancer immunotherapy
CN111019959B (zh) * 2019-12-30 2022-09-13 北京立康生命科技有限公司 一种体外转录mRNA的核苷酸分子、呈递细胞及应用
WO2021150936A1 (en) * 2020-01-22 2021-07-29 City Of Hope Oncolytic virus compositions including il-15 complex and methods for the treatment of cancer
JP2024500189A (ja) 2020-12-21 2024-01-04 アロジーン セラピューティクス，インコーポレイテッド プロテアーゼ活性化ｃｄ４５ゲートｃａｒ
KR20230142470A (ko) 2021-01-29 2023-10-11 알로젠 테라퓨틱스 인코포레이티드 동종이계 세포 산물의 T 세포 인식을 완화하기 위한TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP, 및 RFXANK 중 하나 이상의 녹다운 또는 녹아웃
EP4372088A4 (en) * 2021-07-16 2025-07-23 Noile Immune Biotech Inc ANTI-EGFRVIII ANTIGEN, POLYPEPTIDE, CELL EXPRESSING SAID POLYPEPTIDE, PHARMACEUTICAL COMPOSITION CONTAINING SAID CELL, METHOD FOR PRODUCING SAID CELL, AND POLYNUCLEOTIDE OR VECTOR CONTAINING A SEQUENCE OF BASES ENCODING SAID POLYPEPTIDE
KR20240070579A (ko) * 2021-09-29 2024-05-21 내셔날 리서치 카운실 오브 캐나다 인간화 항-egfrviii 항체 및 이의 항원 결합 단편
US20240042030A1 (en) 2022-07-29 2024-02-08 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
WO2024027835A1 (zh) * 2022-08-05 2024-02-08 北京鼎成肽源生物技术有限公司 靶向EGFRvIII的抗体及其在细胞免疫治疗的应用
CN116284435A (zh) * 2022-09-19 2023-06-23 卡瑞济(北京)生命科技有限公司 EGFRvIII嵌合抗原受体及其用途
CN120936371A (zh) * 2023-03-30 2025-11-11 诺沃库勒有限责任公司 用于使用肿瘤治疗电场和嵌合抗原受体(car)免疫细胞治疗癌症的组合物、系统和方法
WO2025096560A1 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Engineered cells
CN117659196B (zh) * 2023-12-12 2024-08-23 成都优赛诺生物科技有限公司 一种靶向cd7的单域抗体、嵌合抗原受体及其应用
CN119912588B (zh) * 2025-04-01 2025-08-12 浙江大学 嵌合抗原受体、人诱导多能干细胞、髓系前体细胞样巨噬细胞及其制备方法
CN120248142B (zh) * 2025-06-06 2025-09-12 上海兴瑞一达生物科技有限公司 一种共表达cd47和il-15的双靶点嵌合抗原受体、car-t细胞及其应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
EP0651805B1 (en) 1992-07-17 2006-12-13 Dana Farber Cancer Institute Method of intracellular binding of target molecules
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
DK1257632T3 (da) 2000-02-24 2008-01-28 Xcyte Therapies Inc Samtidig stimulering og opkoncentrering af celler
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CN1427891A (zh) * 2000-02-25 2003-07-02 美国政府由(美国)卫生和福利部部长代表 具有提高的细胞毒性和产量的抗EGFRvIII的scFv、基于其的免疫毒素、及其应用方法
WO2008045437A2 (en) 2006-10-09 2008-04-17 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
JP2013544082A (ja) 2010-10-27 2013-12-12 セレクティス 二本鎖破断−誘導変異誘発の効率を増大させる方法
US9249217B2 (en) 2010-12-03 2016-02-02 Secretary, DHHS Bispecific EGFRvIII x CD3 antibody engaging molecules
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN107188969B (zh) 2011-04-08 2021-08-27 美国卫生和人力服务部 抗-表皮生长因子受体变体iii嵌合抗原受体及其用于治疗癌症的用途
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
US20150017136A1 (en) 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
JP6154895B2 (ja) 2012-06-07 2017-06-28 デューク ユニバーシティー ヒト二重特異性ＥＧＦＲｖＩＩＩ抗体結合分子
CN104583230A (zh) * 2012-07-13 2015-04-29 宾夕法尼亚大学董事会 通过共同引入双特异性抗体增强car t细胞的活性
AU2013312838B2 (en) 2012-09-04 2018-11-29 Cellectis Multi-chain chimeric antigen receptor and uses thereof
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
SG11201505896YA (en) * 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
EP2968552B1 (en) 2013-03-14 2020-03-11 The Scripps Research Institute Targeting agent antibody conjugates and uses thereof
AU2014266833B2 (en) 2013-05-13 2020-07-02 Cellectis Methods for engineering highly active T cell for immunotherapy
RS65484B1 (sr) 2013-05-13 2024-05-31 Cellectis Cd19 specifični himerni antigenski receptor i njegove primene
DK3004337T3 (da) 2013-05-29 2017-11-13 Cellectis Fremgangsmåde til konstruktion af T-celler til immunoterapi ved brug af RNA-guidet Cas nuklease-system
ES2718399T3 (es) 2013-07-09 2019-07-01 Univ Duke Moléculas que se acoplan a anticuerpos EGFRVIII biespecíficas humanas
WO2015018527A1 (en) 2013-08-07 2015-02-12 Affimed Therapeutics Ag ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII
AU2014368383B2 (en) 2013-12-20 2020-01-16 Cellectis Method of engineering multi-input signal sensitive T cell for immunotherapy
RU2017102769A (ru) 2014-07-29 2018-08-28 Пфайзер Инк. EGFRvIII СПЕЦИФИЧЕСКИЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ ДЛЯ ИММУНОТЕРАПИИ РАКА
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
US10259876B2 (en) 2016-01-21 2019-04-16 Pfizer Inc. Chimeric antigen receptors targeting epidermal growth factor receptor variant III
DK3405490T3 (da) 2016-01-21 2022-01-10 Pfizer Mono- og bispecifikke antistoffer mod epidermal vækstfaktorreceptor variant iii og cd3 og anvendelser deraf

Also Published As

Publication number Publication date
IL260666B2 (en) 2023-02-01
NZ744821A (en) 2023-06-30
US20170210811A1 (en) 2017-07-27
PH12018501473A1 (en) 2019-03-11
DK3405481T5 (da) 2024-09-23
MY192474A (en) 2022-08-23
RU2018130088A3 (enExample) 2020-07-29
RU2018130088A (ru) 2020-02-25
KR20180099890A (ko) 2018-09-05
UA125252C2 (uk) 2022-02-09
SG11201805872SA (en) 2018-08-30
TW201920237A (zh) 2019-06-01
TWI634125B (zh) 2018-09-01
CN108699124A (zh) 2018-10-23
AU2017208834A1 (en) 2018-08-09
DK3405481T3 (da) 2023-04-17
AU2017208834B2 (en) 2021-09-02
JP2021036873A (ja) 2021-03-11
IL260666A (en) 2018-09-20
JP6823659B2 (ja) 2021-02-03
BR112018014585A2 (pt) 2018-12-11
TWI755547B (zh) 2022-02-21
JP7198797B2 (ja) 2023-01-04
KR102479606B1 (ko) 2022-12-21
US20220227874A1 (en) 2022-07-21
EP3405481A1 (en) 2018-11-28
JP2019506394A (ja) 2019-03-07
EA201891641A1 (ru) 2019-01-31
ES2942362T3 (es) 2023-05-31
EP3405481B1 (en) 2023-01-18
US20190144550A1 (en) 2019-05-16
IL260666B (en) 2022-10-01
US11267892B2 (en) 2022-03-08
WO2017125830A1 (en) 2017-07-27
SG10202111458RA (en) 2021-11-29
PH12018501473B1 (en) 2023-08-02
US10259876B2 (en) 2019-04-16
CA2954014A1 (en) 2017-07-21
TW201734038A (zh) 2017-10-01
RU2751662C2 (ru) 2021-07-15
SA518392058B1 (ar) 2023-02-12

Similar Documents

Publication Publication Date Title
NZ744821A (en) Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
MX2020012573A (es) Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b.
PH12020551160A1 (en) Chimeric antigen receptors targeting cd70
PH12019500193A1 (en) Chimeric antigen receptors targeting bcma and methods of use thereof
PH12019502637A1 (en) Chimeric antigen receptors targeting flt3
MX2021010471A (es) Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr.
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
MX2018002166A (es) Conjugados anticuerpo anti-dll3-farmaco y metodos de uso.
TW201613962A (en) Fabs-in-tandem immunoglobulin and uses thereof
PH12014502437A1 (en) Anti-egfr antibodies and uses threof
MX2017003247A (es) Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
MY175708A (en) Dna antibody constructs and method of using same
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
MX2017011344A (es) Anticuerpos diseñados de sitio específico y métodos de uso.
TW201613971A (en) Anti-epidermal growth factor receptor (EGFR) antibodies
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.